294 patents currently held
36 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.
The next term ends in Nov 2026. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
72
Ending by 2030
Nov 2026
Next term end
190
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jun 2031 · High confidence
Also notable
Ends Jun 2031 · Low confidence
Also notable
Ends Jun 2031 · Medium confidence
Also notable
Ends Jun 2031 · High confidence
Also notable
Ends Oct 2031 · Medium confidence
Also notable
Ends Jun 2031 · High confidence
Also notable
Ends Mar 2030 · Medium confidence
Also notable
Ends Jan 2027 · High confidence
Delivery of RNA to Trigger Multiple Immune Pathways
US 11,291,682
Cited by 42 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2031. A terminal disclaimer caps this term to an earlier patent's.
Immunisation of Large Mammals with Low Doses of RNA
US 11,655,475
Cited by 41 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2031. A terminal disclaimer caps this term to an earlier patent's.
Vaccine for Eliciting Immune Response Comprising Lipid Formulations and RNA Encoding Multiple Immunogens
US 11,638,694
Cited by 14 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2031. A terminal disclaimer caps this term to an earlier patent's.
Pegylated Liposomes for Delivery of Immunogen-Encoding RNA
US 11,759,422
Cited by 50 later US patents, top 1% of utility patents granted in 2023 in our data. Protection runs to 2031. A terminal disclaimer caps this term to an earlier patent's.
Antigen Delivery Platforms
US 11,639,370
Cited by 35 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2031. A terminal disclaimer caps this term to an earlier patent's.
Delivery of RNA to Different Cell Types
US 11,026,964
Cited by 46 later US patents, top 5% of utility patents granted in 2021 in our data. Protection runs to 2031.
Adjuvanting Meningococcal Factor H Binding Protein
US 8,398,988
Cited by 56 later US patents, top 10% of utility patents granted in 2013 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2030.
Outer Membrane Vesicle (OMV) Vaccine Comprising N. Meningitidis Serogroup B Outer Membrane Proteins
US 8,273,360
Cited by 62 later US patents, top 10% of utility patents granted in 2012 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 7 fees due Dec 4 to 30, 2026 · next Dec 4
- 16 fees due Jan 4 to 30, 2027 · next Jan 4
- 7 fees due Feb 8 to 28, 2027 · next Feb 8
- 7 fees due Mar 1 to 26, 2027 · next Mar 1
- 7 fees due Apr 3 to 24, 2027 · next Apr 3
- 9 fees due May 3 to 28, 2027 · next May 3
- 8 fees due Jun 1 to 26, 2027 · next Jun 1
- 12 fees due Jul 2 to 30, 2027 · next Jul 2
- 8 fees due Aug 4 to 27, 2027 · next Aug 4
- 12 fees due Sep 3 to 30, 2027 · next Sep 3
- 7 fees due Oct 2 to 26, 2027 · next Oct 2
- 2 fees due Nov 12 to 17, 2027 · next Nov 12
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
- 9 terms have ended since Aug 23, 2026
- Oct 28 US 8,871,491 Capsular Gram-Positive Bacteria Bioconjugate Vaccines · lapsed on the fee record
- Oct 14 US 8,858,957 GAS57 Mutant Antigens and GAS57 Antibodies · lapsed on the fee record
- Oct 11 US 11,466,292 Compositions and Methods of Treatment · lapsed on the fee record
- Oct 2 US 10,086,060 Immunogenic Proteins and Compositions · lapsed on the fee record
- Sep 20 US 11,446,370 Bioconjugates of E. Coli O-Antigen Polysaccharides, Methods of Production Thereof, and Methods of Use Thereof · lapsed on the fee record
- Sep 6 US 8,192,747 Live Attenuated Rotavirus Vaccine for Oral Administration · term ended
- Aug 30 US 11,426,455 Immunogenic Composition Comprising Staphylococcal Antigens · lapsed on the fee record
- Aug 28 US 10,058,603 Vaccine · lapsed on the fee record
- Aug 26 US 8,815,253 Compositions for Inducing Immune Responses · lapsed on the fee record
What they patent
The largest of its 190 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,156,894 | Chimeric, Hybrid and Tandem Polypeptides of Meningococcal NMB1870 In force · Medium confidence | In force | Medium confidence | |
| US 9,789,179 | Immunogenic Composition In force · High confidence | In force | High confidence | |
| US 10,279,033 | Vaccine Comprising Streptococcus Pneumoniae Capsular Polysaccharide Conjugates In force · Medium confidence | In force | Medium confidence | |
| US 8,273,360 | Outer Membrane Vesicle (OMV) Vaccine Comprising N. Meningitidis Serogroup B Outer Membrane Proteins In force · High confidence | In force | High confidence | |
| US 8,980,277 | Hybrid and Tandem Expression of Neisserial Proteins In force · High confidence | In force | High confidence | |
| US 8,398,983 | Immunogenic Composition In force · High confidence | In force | High confidence | |
| US 9,259,460 | Combination Vaccines with Low Does of Hib Conjugate In force · Medium confidence | In force | Medium confidence | |
| US 10,881,721 | Regimens for Immunisation With Meningococcal Conjugates In force · Medium confidence | In force | Medium confidence | |
| US 10,555,999 | Influenza Vaccine In force · High confidence | In force | High confidence | |
| US 11,564,984 | Influenza Vaccine In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 294: 36 patents in force now held by others · 207 patents ended · 113 applications pending · 308 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.